Based at Duke University School of Medicine in Durham, North Carolina, the Duke Food Allergy Initiative - DFAI supports a number of clinical intervention studies to reduce the risks of peanut allergy, including “Mucosal Immunotherapy for Peanut Allergy in Young Children” using immunotherapy to reduce sensitization to peanut protein in susceptible infants (9 – 36 months) and an oral immunotherapy (OIT) trial of children 1-6 years with peanut allergy to see if exposure to peanut protein induces long term tolerance.

Similar investigations into oral immunotherapy with children and teenagers who have peanut allergy have been successfully undertaken at the University of Cambridge (UK) in a three year desensitization program. Researchers are currently focused on how the results from OIT can become a widely available clinical treatment.

Peanut Bureau of Canada